Sareum Hldgs Plc (SAR) - Total Liabilities

Latest as of June 2025: £1.95 Million GBP ≈ $2.62 Million USD

Based on the latest financial reports, Sareum Hldgs Plc (SAR) has total liabilities worth £1.95 Million GBP (≈ $2.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SAR cash flow metrics to assess how effectively this company generates cash.

Sareum Hldgs Plc - Total Liabilities Trend (2004–2025)

This chart illustrates how Sareum Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. Check Sareum Hldgs Plc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Sareum Hldgs Plc Competitors by Total Liabilities

The table below lists competitors of Sareum Hldgs Plc ranked by their total liabilities.

Company Country Total Liabilities
DRC Systems India Limited
NSE:DRCSYSTEMS
India Rs406.32 Million
Rimfire Pacific Mining Ltd
AU:RIM
Australia AU$2.31 Million
TT Vision Holdings Berhad
KLSE:0272
Malaysia RM30.83 Million
Cubic Digital Technology Co Ltd
SHE:300344
China CN¥144.52 Million
Hawthorn Resources Ltd
AU:HAW
Australia AU$1.59 Million
Philippos Nakas S.A
AT:NAKAS
Greece €12.43 Million
MMC Sanayi ve Ticari Yatirimlar AS
IS:MMCAS
Turkey TL10.52 Million
Siab Holdings Bhd
KLSE:0241
Malaysia RM636.07 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Sareum Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SAR market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sareum Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sareum Hldgs Plc (2004–2025)

The table below shows the annual total liabilities of Sareum Hldgs Plc from 2004 to 2025.

Year Total Liabilities Change
2025-06-30 £1.95 Million
≈ $2.62 Million
+199.08%
2024-06-30 £653.00K
≈ $876.92K
-24.68%
2023-06-30 £867.00K
≈ $1.16 Million
+90.55%
2022-06-30 £455.00K
≈ $611.02K
+60.12%
2021-06-30 £284.15K
≈ $381.59K
+43.12%
2020-06-30 £198.54K
≈ $266.62K
+35.13%
2019-06-30 £146.93K
≈ $197.31K
-19.91%
2018-06-30 £183.46K
≈ $246.36K
+17.95%
2017-06-30 £155.53K
≈ $208.87K
+56.24%
2016-06-30 £99.55K
≈ $133.69K
+47.61%
2015-06-30 £67.44K
≈ $90.57K
+2.48%
2014-06-30 £65.81K
≈ $88.38K
-17.66%
2013-06-30 £79.92K
≈ $107.33K
-34.96%
2012-06-30 £122.87K
≈ $165.01K
+26.67%
2011-06-30 £97.00K
≈ $130.26K
0.00%
2010-06-30 £97.00K
≈ $130.26K
+86.54%
2009-06-30 £52.00K
≈ $69.83K
-88.15%
2008-06-30 £439.00K
≈ $589.54K
-62.70%
2007-06-30 £1.18 Million
≈ $1.58 Million
+102.93%
2006-06-30 £580.00K
≈ $778.89K
+22.88%
2005-06-30 £472.00K
≈ $633.85K
-41.73%
2004-06-30 £810.00K
≈ $1.09 Million
--

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$3.75 Billion
£2.80 Billion GBP
Market Cap Rank
#24538 Global
#227 in UK
Share Price
£20.25
Change (1 day)
-1.22%
52-Week Range
£12.00 - £27.50
All Time High
£457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more